アジアの大腸がん治療薬市場

Technavioが発行した調査報告書(IRTNTR7888)
◆英語タイトル:Colorectal Cancer Therapeutics Market in APAC 2015-2019
◆商品コード:IRTNTR7888
◆発行会社(リサーチ会社):Technavio
◆発行日:2015年12月16日
◆ページ数:106
◆レポート形式:英語 / pdf
◆納品方法:Eメール
◆調査対象地域:アジア太平洋
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥327,000見積依頼/購入/質問フォーム
Five UserUSD3,500 ⇒換算¥381,500見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,500 ⇒換算¥490,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、アジアの大腸がん治療薬市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、アジアの大腸がん治療薬市場規模及び予測、投与経路(ROA)別分析、市場シェア、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

・エグゼクティブサマリー
・市場概観
・業界の構造分析
・疾患概要
・アジアの大腸がん治療薬市場:市場規模及び予測
・アジアの大腸がん治療薬市場:投与経路(ROA)別分析
・アジアの大腸がん治療薬市場:成長要因
・アジアの大腸がん治療薬市場:課題
・市場シェア
・市場動向
・競争状況
・主要企業(ベンダー)分析
...

※上記の和訳は最新内容ではない場合があります。
【レポートの概要】

Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain. Colorectal cancer can be classified into four broad stages. Colorectal cancer can be treated using surgical, chemotherapeutic, biologic, and radiation therapies.

Technavio’s analysts forecast the colorectal cancer therapeutics market in APAC to grow at a CAGR of 6.32% over the period 2014-2019.

[Covered in this report]
The report covers the current scenario and the growth prospects of the colorectal cancer therapeutics market in APAC for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of colorectal cancer. The colorectal cancer therapeutics market in APAC is segmented based on lines of chemotherapy: first-line chemotherapy and second-line chemotherapy.

Technavio’s report, Colorectal Cancer Therapeutics Market in APAC 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC; it also covers the landscape of the colorectal cancer therapeutics market in APAC and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

[Key regions]
• APAC
• China
• Japan

[Key vendors]
• Amgen
• Bayer
• Bristol-Myers Squibb
• Chugai Pharmaceuticals
• Merck
• Sanofi

[Other prominent vendors]
• Accord Healthcare
• Advenchen Laboratories
• Aeterna Zentaris
• AstraZeneca
• AVEO Oncology
• Bavarian Nordic
• Biothera
• Boehringer Ingelheim
• Boston Biomedical
• Cancer Prevention Pharmaceuticals
• Celator Pharmaceuticals
• Daiichi Sankyo
• Debiopharm
• Eisai
• Eli Lilly
• EpicentRx
• GlaxoSmithKline
• Hutchison Medipharma
• Immodulon Therapeutics
• Immunomedics
• MacroGenics
• Merrimack Pharmaceuticals
• MolMed
• Mologen
• Morphotek
• Mylan
• Nektar Therapeutics
• Oncothyreon
• Otsuka Pharmaceutical
• PledPharma
• Precision Biologics
• PsiOxus Therapeutics
• Sun Pharmaceutical
• Symphogen
• Taiho
• Takeda
• Teva Pharmaceuticals
• ThromboGenics
• Xbiotech
• Yakult Honsha

[Market Driver]
• Increase in aging population
• For a full, detailed list, view our report

[Market challenge]
• Unknown disease etiology
• For a full, detailed list, view our report

[Market trend]
• Rise in public awareness
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Vectibix

PART 03: Product profiles
• Stivarga
• Erbitux
• Xeloda
• Avastin
• Zaltrap

PART 04: Market research methodology
• Research methodology
• Economic indicators

PART 05: Introduction
• Key market highlights

PART 06: Disease overview
• Understanding the disease
• High risk factors
• Signs and symptoms
• Pathophysiology
• Diagnosis
• Staging
• Biomarker testing
• Epidemiology
• Treatment

PART 07: Pipeline portfolio
• Information on pipeline candidates

PART 08: Market landscape
• Market overview
• Market size and forecast
• Colorectal cancer therapeutics market in Japan
• Colorectal cancer therapeutics market in China
• Five forces analysis

PART 09: Market segmentation by based on the type of molecules
• Small molecules
• Biologics

PART 10: Market segmentation by route of administration
• Oral
• Parenteral

PART 11: Market segmentation by lines of chemotherapy
• First-line chemotherapy
• Second-line chemotherapy

PART 12: Market drivers

PART 13: Impact of drivers

PART 14: Market challenges

PART 15: Impact of drivers and challenges

PART 16: Market trends

PART 17: Vendor landscape
• Competitive scenario
• Market share analysis 2014
• Other prominent vendors
• Amgen

PART 18: Key vendor analysis
• Bayer HealthCare
• Bristol-Myers Squibb
• Chugai Pharmaceutical
• Merck
• Sanofi

PART 19: Appendix
• List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: High risk factors for colorectal cancer
Exhibit 03: Signs and symptoms of colorectal cancer
Exhibit 04: Diagnostic tests for colorectal cancer
Exhibit 05: Staging for colon cancer
Exhibit 06: Staging for rectal cancer
Exhibit 07: Types of genes
Exhibit 08: Estimated incidence, mortality, and five-year prevalence per 100,000 in APAC 2012
Exhibit 09: Colorectal cancer mortality rates in APAC 2012 (rate per 100,000 population)
Exhibit 10: Incidence rates of colorectal cancer in Asia, 2011 (rate per 100,000 population)
Exhibit 11: Estimated incidence in adult population in APAC 2012
Exhibit 12: Colorectal cancer incidence and mortality rates in top seven countries in Asia regions, 2008, males
Exhibit 13: Colorectal cancer incidence and mortality rates in top seven countries in Asia regions, 2008, females
Exhibit 14: Treatment options for colorectal cancer
Exhibit 15: Types of surgical procedure for colorectal cancer
Exhibit 16: Types of radiation therapy for colorectal cancer
Exhibit 17: Types of targeted therapy
Exhibit 18: Summary of approved cancer drugs for colon cancer
Exhibit 19: Pipeline molecules for colorectal cancer
Exhibit 20: Colorectal cancer therapeutics market in APAC ($ billions)
Exhibit 21: Colorectal cancer therapeutics market in Japan 2014-2019 ($ billions)
Exhibit 22: Colorectal cancer therapeutics market in China 2014-2019 ($ millions)
Exhibit 23: Five forces analysis
Exhibit 24: Colorectal cancer therapeutics market in APAC segmented by molecule type
Exhibit 25: Colorectal cancer therapeutics market in APAC segmented by route of administration
Exhibit 26: Summary of chemotherapy drugs for the treatment of colorectal cancer
Exhibit 27: Use of branded targeted therapies in China and Japan 2013
Exhibit 28: Drivers of colorectal cancer therapeutics market in APAC
Exhibit 29: Impact of drivers
Exhibit 30: Challenges of colorectal cancer therapeutics market in APAC
Exhibit 31: Impact of drivers and challenges
Exhibit 32: Trends of colorectal cancer therapeutics market in APAC
Exhibit 33: Vectibix: YoY revenue and growth rate in Japan 2011-2013 ($ millions)
Exhibit 34: Amgen: Key takeaways
Exhibit 35: Bayer: Key takeaways
Exhibit 36: Bristol-Myers Squibb: Key takeaways
Exhibit 37: Avastin: YoY revenue and growth rate in Japan 2010-2014 ($ millions)
Exhibit 38: Xeloda: YoY revenue and growth rate in Japan 2010-2014 ($ millions)
Exhibit 39: Chugai Pharmaceutical: Key takeaways
Exhibit 40: Merck: Key takeaways
Exhibit 41: Sanofi: Key takeaways
Exhibit 42: Amgen: Business segmentation by revenue 2014
Exhibit 43: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 44: Amgen: Geographical segmentation by revenue 2014
Exhibit 45: Bayer HealthCare: Business segmentation by revenue 2014
Exhibit 46: Bayer HealthCare: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 47: Bayer HealthCare: Geographical segmentation by revenue 2014
Exhibit 48: Bristol-Myers Squibb: Products segmentation by revenue FY2014
Exhibit 49: Bristol-Myers Squibb: Revenue comparison by product segmentation by FY2013 and FY2014
Exhibit 50: Bristol-Myers Squibb: Geographical segmentation by FY2014 ($ millions)
Exhibit 51: Bristol-Myers Squibb: Revenue comparison by geographical segment by FY2013 and FY2014 ($ millions)
Exhibit 52: Chugai Pharmaceuticals: Business segmentation by revenue 2014 (therapeutics)
Exhibit 53: Chugai Pharmaceuticals: Geographical segmentation by revenue 2014
Exhibit 54: Merck: Business segmentation by revenue 2014
Exhibit 55: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 56: Merck: Geographical segmentation by revenue 2014
Exhibit 57: Sanofi: Business segmentation by revenue 2014
Exhibit 58: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 59: Sanofi: Geographical segmentation by revenue 2014



【掲載企業】

Amgen, Bayer Healthcare, Bristol-Myers Squibb, Chugai Pharmaceutical, Merck, Sanofi, Accord Healthcare, Advenchen Laboratories, Aeterna Zentaris, AstraZeneca, AVEO Oncology, Bavarian Nordic, Biothera, Boehringer Ingelheim, Boston Biomedical, Celator Pharmaceuticals, Cancer Prevention Pharmaceuticals, Daiichi Sankyo, Debiopharm, Eisai, Eli Lilly, EpicentRx, GlaxoSmithKline, Hutchison Medipharma, Immodulon Therapeutics, Immunomedics, MacroGenics, Merrimack Pharmaceuticals, Morphotek, Mologen, MolMed, Mylan, Nektar Therapeutics, Oncothyreon, Otsuka Pharmaceutical, Precision Biologics, PsiOxus Therapeutics, PledPharma, Sun Pharmaceutical, Symphogen, Taiho, Takeda, Teva, ThromboGenics, Xbiotech, Yakult Honsha.

【リサーチ方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ アジアの大腸がん治療薬市場(Colorectal Cancer Therapeutics Market in APAC 2015-2019)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆